When suicidal thoughts become a psychiatric emergency, waiting weeks for traditional antidepressants may not be enough. A new Stanford study explores an emerging rapid-intervention strategy using IV ketamine followed by low-dose buprenorphine to help sustain anti-suicidal effects in patients with major depression. Here’s what the science says—and why this could represent a meaningful shift in interventional psychiatry.

ketamine has rapidly emerged as one of the most effective treatments for treatment-resistant depression (TRD).

But with its growing use, a critical question comes up:

👉 Does ketamine cause tachyphylaxis (loss of effect) or dependence over time?

For patients in Reno, Nevada, considering this therapy, it’s essential to separate evidence from assumption—especially given ketamine’s history outside of medical settings.